Holen Sie sich die Stockscreener-App
10.45
2.55%
-0.13
Schlusskurs vom Vortag:
$10.58
Offen:
$10.49
24-Stunden-Volumen:
95,246
Relative Volume:
0.05
Marktkapitalisierung:
$1.35B
Einnahmen:
$8.40M
Nettoeinkommen (Verlust:
$-237.42M
KGV:
-5.439
EPS:
-1.9213
Netto-Cashflow:
$-377.03M
1W Leistung:
-0.39%
1M Leistung:
-62.64%
6M Leistung:
-61.59%
1J Leistung:
+141.45%
1-Tages-Spanne:
$10.27
$10.51
1-Wochen-Bereich:
$10.25
$11.92
52-Wochen-Spanne:
$3.76
$31.35
Alumis Inc Stock (ALMS) Company Profile
Firmenname
Alumis Inc
Sektor
Branche
Telefon
650-231-6625
Adresse
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
10.43 | 1.37B | 8.40M | -237.42M | -377.03M | -1.9213 |
VRTX
Vertex Pharmaceuticals Inc
|
522.91 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.18 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.89 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.95 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
207.72 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-11 | Eingeleitet | Raymond James | Strong Buy |
| 2026-02-25 | Eingeleitet | Stifel | Buy |
| 2026-01-21 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-07-25 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-10 | Fortgesetzt | Guggenheim | Buy |
| 2025-01-30 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-31 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-10-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-07-23 | Eingeleitet | Guggenheim | Buy |
| 2024-07-23 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-23 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Alumis Inc Aktie (ALMS) Neueste Nachrichten
Alumis (ALMS) Plans to Advance Envudeucitinib After LUMUS Missed in the Overall Population - Yahoo Finance
Alumis at Wells Fargo conference: lupus setback sharpens strategy By Investing.com - Investing.com Canada
ALMS Stock Clocks Worst Day After 57% Drop — What Drove The Selloff? - stocktwits.com
Price-Driven Insight from (ALMS) for Rule-Based Strategy - Stock Traders Daily
Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven DiseasesSlideshow (NASDAQ:ALMS) 2026-09-04 - Seeking Alpha
Alumis to Participate in Upcoming September Investor Conferences - The Manila Times
Four public talks are planned for September. Alumis will stream them online. - Stock Titan
Apple, Tesla, Nvidia, Medtronic, Alumis, Robinhood, Fervo, and More Stocks That Explain Today's Market -- Barrons.com - moomoo.com
Is Alumis (ALMS) Overvalued After Its 121% One Year Return? - Yahoo Finance
Alumis stock downgraded at Guggenheim (ALMS:NASDAQ) - Seeking Alpha
Why Alumis (ALMS) Is Down 56.2% After Mixed Phase 2b Lupus Data Spotlight Biomarker Strategy - Yahoo Finance
Guggenheim Downgrades Alumis to Neutral From Buy - marketscreener.com
Alumis (ALMS) Looks Pricey After Its Lupus Trial Miss But Is 3x P B Fair? - Yahoo Finance
Alumis (ALMS) Lead Lupus Drug Missed Phase 2b Trial Endpoints - Yahoo Finance
Guggenheim downgrades Alumis stock rating after trial miss By Investing.com - Investing.com Canada
Guggenheim downgrades Alumis stock rating after trial miss - Investing.com India
Morgan Stanley cuts Alumis stock price target on lupus trial failure By Investing.com - Investing.com South Africa
Alumis (ALMS) Stock Slides As Momentum Traders Refocus On Fundamentals - timothysykes.com
Alumis' Share Price Fall After Envudeucitinib Trial Data Likely Overreaction, Oppenheimer Says - marketscreener.com
This OGE Energy Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday - Benzinga
Oppenheimer Adjusts Price Target on Alumis to $37 From $55, Maintains Outperform Rating - marketscreener.com
Wells Fargo cuts Alumis stock price target on SLE trial results - Investing.com Australia
Morgan Stanley cuts Alumis stock price target on lupus trial failure - Investing.com
Wells Fargo cuts Alumis stock price target on SLE trial results By Investing.com - Investing.com South Africa
Alumis stock plunges 57% after lupus drug trial fails, but psoriasis drug progress continues. - Pluang
Alumis plunges 57% after trial failure; Enovis falls 16% on robotics acquisition news - Pluang
Alumis shares plunge after lupus trial failure, but drug potential remains uncertain - Pluang
Alumis: A Brutal Lupus Setback, But Psoriasis Still Supports Upside (NASDAQ:ALMS) - Seeking Alpha
Alumis Plunges 56% After Lupus Drug Fails Key Trial Goals - finance.biggo.com
Alumis’ TYK2 drug fails in key lupus study - BioPharma Dive
Alumis Shares Plummet 59% After Lupus Study Failure Wipes Out $1.67 Billion - TechStock²
Alumis stock tumbles 55% after lupus drug trial misses goals By Investing.com - Investing.com Nigeria
Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise - Yahoo Finance
Why Is Alumis Stock Falling Tuesday? - Benzinga
Alumis Announces Topline Phase 2b Results for Envudeucitinib in Systemic Lupus Erythematosus - kalkinemedia.com
Alumis falls after TYK2 pill fails lupus study, but CEO sees 'clear path forward' - Endpoints News
Alumis falls after trial setback for lead drug (ALMS:NASDAQ) - Seeking Alpha
Why is Alumis stock collapsing today? By Investing.com - Investing.com Australia
Alumis Phase 2b lupus trial misses primary and secondary endpoints - Yahoo Finance
ALMS Stock Slides As Losses Mount Despite Strong Cash - StocksToTrade
Alumis stock tumbles 55% after lupus drug trial misses goals - Investing.com
Alumis Reports Mixed Phase 2b LUMUS Results for Envudeucitinib in SLE, Highlights IFNGS-High Subgroup and Safety Data - quiverquant.com
Alumis' lupus drug fails mid-stage trial goal - marketscreener.com
Trading Systems Reacting to (ALMS) Volatility - Stock Traders Daily
Alumis (NASDAQ:ALMS) Shares Down 7.9%What's Next? - MarketBeat
What Alumis (ALMS)'s Envudeucitinib Phase 3 Data and Deepening Losses Means For Shareholders - simplywall.st
Equities Analysts Set Expectations for Alumis Q3 Earnings - MarketBeat
H.C. Wainwright reiterates Alumis stock rating at neutral, $25 target - Investing.com
Venture investor’s big move: Latigo Biotherapeutics (ALMS) lands new 14.5% holder - Stock Titan
ALMSAlumis Inc Forecast, Target Price - Finviz
Alumis (NASDAQ:ALMS) Lowered to "Strong Sell" Rating by Wall Street Zen - MarketBeat
Finanzdaten der Alumis Inc-Aktie (ALMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alumis Inc-Aktie (ALMS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pangali Sanam | Chief Legal Officer |
Aug 03 '26 |
Sale |
26.37 |
1,364 |
35,969 |
9,747 |
| Hardiman Roy C. | Chief Business & Strategy Ofcr |
Aug 03 '26 |
Sale |
26.37 |
2,692 |
70,988 |
207,746 |
| Goldstein David M | Chief Scientific Officer |
Aug 03 '26 |
Sale |
26.37 |
2,596 |
68,457 |
30,970 |
| Drappa Jorn | Chief Medical Officer |
Aug 03 '26 |
Sale |
26.37 |
2,447 |
64,527 |
56,892 |
| Bradley Mark Christopher | Chief Development Officer |
Aug 03 '26 |
Sale |
26.37 |
2,572 |
67,824 |
48,533 |
| Pangali Sanam | Chief Legal Officer |
Jul 06 '26 |
Option Exercise |
5.06 |
5,000 |
25,300 |
16,111 |
| Pangali Sanam | Chief Legal Officer |
Jul 06 '26 |
Sale |
28.00 |
5,000 |
140,000 |
11,111 |
0.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):